

## **ERYTECH announces plans to conduct registered initial public offering in the United States**

---

**Lyon (France), July 28, 2015** – ERYTECH Pharma (Euronext Paris - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that the Company plans to conduct a registered initial public offering in the United States.

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The timing and the terms of this initial public offering have not yet been determined.

### **CONTACTS**

#### **ERYTECH**

**Gil Beyen**

*Chairman and CEO*

Tel: +33 4 78 74 44 38

[investors@erytech.com](mailto:investors@erytech.com)

#### **NewCap**

**Julien Perez / Emmanuel Huynh**

Investor relations

**Nicolas Merigeau**

Press relations

Tel: +33 1 44 71 98 52

[erytech@newcap.fr](mailto:erytech@newcap.fr)